$ cat ./records/funded-global-access-to-the-rotavirus-vaccine-for-children-in-dev-2006.txt
Funded global access to the rotavirus vaccine for children in developing countries
[RECORD.TXT] · cat --full
The Gates Foundation invested over $190 million to develop the rotavirus vaccine and ensure its rollout in developing countries, where the virus killed approximately 500,000 children annually from severe diarrheal disease. The Foundation worked to negotiate lower vaccine pricing for low-income markets and funded delivery infrastructure to reach rural communities. By 2023 the vaccine had reached over 100 countries and is credited with preventing hundreds of thousands of child deaths every year.
Source: https://www.gatesfoundation.org/our-work/programs/global-health/vaccines
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Awarded France's Légion d'honneur — the country's highest civilian distinction
Next →
Co-founded the Alliance for a Green Revolution in Africa (AGRA)
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.